论文部分内容阅读
急性早幼粒细胞白血病 (APL)是具有生物学和临床特点的一种特殊类型急性髓细胞白血病。近年来全反式维甲酸 (ATRA)的应用极大地提高完全缓解率和减少了治疗相关死亡率。ATRA与化疗联合应用有助于降低复发率和延长生存期。三氧化二砷 (As2 O3 )治疗初治和复发APL已取得巨大成功。持续分子缓解是APL的治疗目标。早期发现分子复发并给予补救治疗 ,可取得更好的临床治疗效果
Acute promyelocytic leukemia (APL) is a special type of acute myeloid leukemia with biological and clinical features. The use of all-trans retinoic acid (ATRA) in recent years has greatly increased the rate of complete remission and reduced treatment-related mortality. The combination of ATRA and chemotherapy helps to reduce the recurrence rate and prolong survival. Arsenic trioxide (As2O3) has been a great success in the treatment of initial and relapsed APL. Sustained molecular remission is the treatment goal of APL. Early detection of molecular recurrence and rescue treatment can lead to better clinical outcomes